Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 1998

View Archived Issues

3M presents first clinical results for potent new immunomodulator

Genome Therapeutics and ArQule begin high-throughput screening

Elan reacquires Naprelan and Verelan rights from Wyeth-Ayerst

U.S. is country of first launch for DuPont's NNRTI

PathoGenesis in-licenses monobactam antibiotic from Bristol-Myers Squibb

Linezolid in the limelight at ICAAC

Nonimmunosuppressive rotamase inhibitors under study at Guilford for neurological disorders

BASF describes novel inhibitors of cysteine proteases

Canadian team isolates novel anti-HSV agent from Chinese herb

Novel anti-HBV nucleosides presented by Nabi at ICAAC

Merck KGaA, 3DP extend drug discovery agreement for another year

CP-279107 inhibits macrolide-resistant streptococci in vitro and in vivo

Versicor searches for inhibitors of bacterial ligases as novel antibiotics

NC-1175: novel conjugated styryl ketone with ATPase-targeted fungicidal activity

New collaboration into the genetic basis of obesity announced

Bisphosphonate-conjugated antibacterials for targeted drug delivery in bone infections

SmithKline Beecham acquires transdermal nicotine product in Australia and New Zealand

Merck describes new ascomycin derivatives with improved therapeutic potential

Chiroscience identifies new target for autoimmune disease therapy

FDA approves anthracycline with orphan drug status for carcinoma in situ of the bladder

Study suggests beneficial effects of COX-2 inhibition in cerebral ischemia

Preliminary phase II data and preclinical results reported for MK-826

Penederm joins the Mylan family of companies

Bayer's moxifloxacin highlighted at ICAAC; approval to be sought soon

Candidate gene therapy for hemophilia gives promising results in canine studies

Italian marketing approval obtained for metoclopramide nasal spray

Inex, Schwarz drop development of antisense drug for restenosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....